IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2489
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$0
Werner Lanthaler
Evotec SE operates as drug discovery and development partner for pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.
Headcount
4.2K
HQ Base
Pending Verification
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EVO Evotec SE | 47 | 51 | 27 | 38 | - | - | -82.3% | -41.0% | 14.4% | -11.0% | -24.6% | - | - | 0.0x | $0 | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Evotec SE (EVO) receives a "Reduce" rating with a composite score of 47.0/100. It ranks #2489 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Expensive relative to fundamentals — limited margin of safety
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for EVO.
View All RatingsROE proxy -82.3% (sector -1.9%)
GM 14% vs sector 44%, OM -11% vs sector 3%
Capital turnover N/A, R&D intensity 6.4%
Rev growth N/A, 4yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Evotec SE (EVO) as a Reduce with a composite score of 47.0/100 at a current price of $3.33. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
Evotec SE holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.0/100 places it at rank #2489 in our full universe.
No Moat
Medium
Poor
Fair Value
Stable competitive position in a defensive sector.
Vulnerability to macroeconomic shocks and interest rate volatility.
Evotec SE represents a reduce based on multi-factor quantitative performance.
Evotec SE receives a Reduce rating from our analysis, with a composite score of 47.0/100 and 2 out of 5 stars, ranking #2489 out of 7,333 stocks. EVO's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 51/100, EVO shows adequate but unremarkable business quality. The company reports a return on equity of -82.3% (sector avg: -1.9%), gross margins of 14.4% (sector avg: 44.1%), net margins of -24.6% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
EVO registers a value score of just 27/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.27x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
With an investment score of 58/100, EVO exhibits moderate growth-oriented spending. Key growth metrics include a return on assets of -41.0% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
EVO is currently showing below-average momentum at 38/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.76 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 62/100, EVO exhibits average financial resilience. Key stability metrics include a beta of 0.76 and a debt-to-equity ratio of 0.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
Evotec SE's short interest score of 33/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include micro-cap liquidity risk. At $0 (micro-cap), EVO carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Evotec SE is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2489 of 7,333 overall (66th percentile). Key comparisons include ROE of -82.3% trailing the -1.9% sector median and operating margins of -11.0% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While EVO currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Value (27) would have the largest impact on the composite score.
ROE 4234% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 67% BELOW SECTOR MEDIAN
Op. Margin 538% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Amgen acquired Dark Blue Therapeutics for up to $840 million to strengthen its oncology pipeline. Dark Blue's lead candidate DBT 3757 targets acute myeloid leukemia and acute lymphoblastic leukemia. The acquisition complements Amgen's targeted protein degradation research and advances its early-stage cancer medicine strategy.
CINCINNATI, February 17, 2026--Tide®, America’s #1 trusted laundry detergent brand, continues to deliver an unmatched level of clean. With the national launch of Tide evo – a 100% concentrated, waterless tile with six cleaning layers – Tide is introducing an entirely new product format that addresses modern consumers’ everyday laundry needs and preferences. Tide evo activates instantly in cold water, leveraging cleaning technologies like all-in-one scrubbers, pre-treaters, brighteners and freshe
ATR's next-generation hybrid turboprop evolution lives at the intersection of European industrial policy.
Evotec (XTRA:EVT) is back on investors’ radars after recent share price moves, with the stock showing a mix of short term gains and longer term declines that highlight contrasting performance snapshots. See our latest analysis for Evotec. The recent 7 day share price return of 14.08% and 30 day share price return of 20.28% contrast with a 1 year total shareholder return of 21.96% and 5 year total shareholder return of 78.72%. This suggests short term momentum against a weaker long term...
Kazia Therapeutics reported a patient with stage IV triple-negative breast cancer achieved an initial immune-complete response when treated with paxalisib combined with pembrolizumab and standard chemotherapy, showing a profound radiologic response in a highly aggressive cancer subtype.